FDA al­lows com­pounders to repack­age, com­bine propo­fol amid Covid-19

Af­ter al­low­ing com­pounders and out­sourc­ing fa­cil­i­ties to com­pound 13 drugs need­ed to treat pa­tients on ven­ti­la­tors dur­ing the coro­n­avirus dis­ease (Covid-19) pub­lic health emer­gency, the FDA says it will al­low com­pounders to repack­age or com­bine propo­fol to meet hos­pi­tals’ needs.

“FDA has re­ceived re­ports from some hos­pi­tals that they are hav­ing dif­fi­cul­ty ob­tain­ing ad­e­quate sup­plies of FDA-ap­proved propo­fol in­jectable emul­sion (propo­fol) prod­ucts, 10 mil­ligram (mg) per mil­li­liter (mL), in the pre­sen­ta­tions used to sup­port Covid-19 pa­tients who have been se­dat­ed and in­tu­bat­ed, or for oth­er pro­ce­dures in­volved in the care of such pa­tients,” FDA writes.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.